Immune and Inflammatory Indices in Peripheral Blood Predict Prognosis of Glioma and Correlate With Grades and Subtypes

Overview

Our study considered the relevant immune and inflammatory indices, such as immunoglobulin kappa light chain, TNF, and CD4+ Helper T lymphocyte% in a multi-institutional study with a large patient cohort (n=1282) from the east, northeast, and southeast of China. Our study shed light on the association of peripheral immune system status with prognosis, tumor grade, and subtype of glioma, which can potentially benefit future diagnostic and prognostic processes of glioma given its noninvasive nature. Moreover, the preoperative inflammatory status can be leveraged for timely interventions to reverse the immunosuppressive status of cancer patients and enhance anti-tumour immunity of glioma.

Full Title of Study: “Preoperative Immune and Inflammatory Indices in Peripheral Blood Predict Prognosis of Glioma and Correlate With Grades and Subtypes: A Prospective Multi-Institutional Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: April 6, 2022

Interventions

  • Other: Detection of Immune and Inflammatory Indices in Peripheral Blood
    • We detected immune and inflammatory indices in peripheral blood at each patient’s at first hospitalizatin from October 13th, 2006, to April 6th, 2022.

Arms, Groups and Cohorts

  • primary glioma patients
    • We collected the information of clinical characteristics, inflammatory factors and immune factors of patients with primary glioma.

Clinical Trial Outcome Measures

Primary Measures

  • all-cause mortality
    • Time Frame: 16 years
    • For this study, the endpoint was all-cause mortality. Time zero was set at the time of resection of the primary tumor.

Participating in This Clinical Trial

Inclusion Criteria

  • glioma grading and classification histologically verified in a resection or biopsy specimen according to 2016 WHO criteria; – age > 18 years; – primary malignant glioma; – the duration of follow-up > 3 months; – available data of lymphocyte subsets, cytokines, immune proteins and immune complements measured at the patient's first hospitalization. Exculsion Criteria: – current infectious disease, hyperpyrexia, hematological disease, diabetes mellitus, serious heart disease, hypertension, metabolic syndrome, severe renal or hepatic dysfunction, other cancer, autoimmune disease, inflammatory disease, or medication usage related to an inflammatory condition; – prior cancer-specific pretreatment, such as chemotherapy or radiotherapy;

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Sun Yat-sen University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Yonggao Mou, Clinical Professor – Sun Yat-sen University
  • Overall Contact(s)
    • Sheng Zhong, M.D., 18743037749, zhongsheng@sysucc.org.cn

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.